Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Research Associate, Genomics and Off-Target Assay Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Feb 1, 2023

View more

Discipline
Regulatory, Science/R&D, Research, Genomics
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Genetown, Best Places to Work

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

We are looking to hire a Senior Research Associate to the growing Genomic Innovation team! As a SRA, you will help develop and evaluate new next generation sequencing (NGS) methods to characterize off-target transgene insertions and address emerging research questions. You will also apply established high throughput NGS methods to help support the characterization and quantitation of unintended off-target genome editing with CRISPR/Cas9. You will work on various projects across different stages of therapeutic development. Additional responsibilities include:

Apply molecular biology techniques such as DNA purification, shearing, adapter ligation, PCR, NGS library purification and quantification Work with other members of the team on development of creative design for new assays and implement testing and development of those assays in the lab Evaluate, develop, and conduct genome-wide off-target experiments to characterize guides for therapeutic development Troubleshoot and optimize NGS and long-read assays in collaboration with colleagues Generate cell material for evaluation of off-target methods with CROs or within the GxI team Accurately document project and sample information, protocols, and experimental details through the Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN)

About you:

We are looking for a candidate with a MS in Molecular Biology, Biotechnology, or related field with 0-2 years of experience in an academic or industrial setting; or a BS with 2+ years of relevant lab work experience such as an internship, co-op or previous work experience at a biotech/pharma company or in a university research lab. Candidates must have enthusiasm to learn and grow and the ability to work as part of a cross-functional team.

Candidates should have hands on experience with two or more of the following: PCR, gel electrophoresis, sequencing methods (Sanger, Illumina NGS, PacBio, and/or Oxford nanopore), bead-based clean-up, DNA/RNA purification, cell culture or genome editing with CRISPR/Cas9.

Meet your future team:

The Genomic Innovation Team is a fun, energetic, and passionate group of individuals, who are focused on applications of genomics to advance research and innovation in gene editing. You will report directly to a Senior Scientist in the Genomics Innovation Team. This hiring manager develops and evaluates genomics methods for off-target characterization and supports genotoxicity documentation for Health Authority regulatory interactions. The breadth of exposure to cutting edge gene therapy development will provide the candidate with exposure to the full spectrum of CRISPR therapeutic development in vivo and in cell-based therapies engineered with CRISPR.

The team is currently working mostly onsite to execute NGS workflows in a wet-lab environment. Therefore, we require a candidate to be currently local to Cambridge MA, or open to relocating. While much of the day-to-day operations require wet-lab work, our team is focused on building not just technical expertise but fostering an environment for growth of young scientists interested in a career in therapeutic biotechnology. If you join our team, you can expect to join a hardworking and collaborative environment. We look forward to fostering your skills, learning from your experiences, and building a larger team that will make a difference in patient’s lives.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert